Dry eye disease drug candidate failed to meet key treatment goals in trial

The AP (1/21) reports that Inspire Pharmaceuticals Inc. said Prolacria (diquafosal), its drug candidate for dry eye disease, “failed to meet key treatment goals” in a Phase 3 clinical trial of 490 patients lasting six weeks.
The Triangle Business Journal (1/21, Vinluan) reports that Inspire “said that its product, Prolacria, did not meet primary or secondary goals set for the drug in the trials.” Inspire President and CEO Christy Shaffer said in a statement that the company “will be conducting a thorough review of the program before determining next steps, if any.” In 2002, under the name INS365, tests of Prolacria “showed the drug worked no better than saline.”

For information on dry eye and related diseases visit youreyesite.com

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: